Ricketts to head PharmaDiagnostics
This article was originally published in Clinica
PharmaDiagnostics, a Belgian firm specialising in label-free screening technology, has appointed David Ricketts as CEO. Dr Ricketts, who was a consultant to the Zellik-based company before the appointment, began his career in Glaxo Group Research. He subsequently held various scientific, sales and marketing and business development roles for a number of drug discovery and life sciences firms. Dr Ricketts will be responsible for overseeing PharmaDiagnostics' growth, as it advances commercialisation of its assays and development of its technology pipeline. The company's localised surface plasmon resonance technology allows label-free screening to be carried out without the need for expensive specialised equipment.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.